Hologic Inc

Hologic — Debt Investor Presentation (June 2012)

53 slides from Hologic's debt investor presentation, Jun 29, 2012

  1. Slide 1: Company Presentation to Prospective Lenders

    Exhibit 99.1 Exhibit The July HOLOGIC® women’s 2012 99.1 health Company Presentation to Prospective Lenders

  2. Slide 2: Agenda

    The women’s Executive Agenda 2Appendix HOLOGIC A: B: Summary Disclaimers Non-GAAP health company Transaction Adjustments Merits Company Overview Key Credit Strengths Historical Financial Review

  3. Slide 3: Transaction Summary

    Transaction On of As — 3The HOLOGIC approximately $300 $1,000 $1,750 $750 On Expected $2,449 $897 of April women’s 100% acquisition combination LTM June million 30, million cash 31-Mar-2012, 18, Summary closing 2012 health 2012 transaction isof Revolving of $3.9 subject of Hologic, Senior pro Hologi

  4. Slide 4: Sources and Uses

    Total The $82.75 ($ Sources Cash Revolving Term New 4¹ Atinclosing womens HOLOGICmillions) Senior and Sources Loan per &Marketable Uses Credit Uses Share ABof Unsecured health Facility $4,326 thePurchase Facility1 company Total Securities 1,000 1,750 Notes Gen-ProbePrice — Uses Fees, 750 Refinance o

  5. Slide 5: Pro Forma Capitalization

    The Pro $82.75 ($ 3/24/2012 Hologic Cash1 New Total 2.00% Capital Total inForma Estimated Pro women’s millions) Term Revolving Senior Secured Guaranteed $1,256 per Adj. Convertible Pro Loan Capitalization Share Unsecured Principal health $(826) Debt Forma Exchange Forma Debt Net Lease Facility Lever

  6. Slide 6: Agenda

    The women’s Executive Agenda Transaction 6Appendix HOLOGIC A: B: Summary Merits Disclaimers Non-GAAP healthCompany company Adjustments Overview Key Credit Strengths Historical Financial Review

  7. Slide 7: The Combined Company Overview

    Combined The LTM Pro Revenue Adjusted % ($mm) PF Margins Adjusted Forma women’s combination transaction combined as Public of$1,862 EBITDA Company Mar-2012 34% 37% EBITDA health Company positions 32% $587 of$634 toHologic company Overview 34% $2,449 w/presentations $188 expects Synergies the and com

  8. Slide 8: The Compelling Strategic Rationale

    Combination The Compelling Diagnostics molecular upside •automation additional #1 Gen-Probe Strengthens Cost Enables Provides Streamlines Enhances Strong women’s Stand-alone synergies growth further diagnostics disposables access recurring in development franchise Strategic of development and health

  9. Slide 9: Market Leader in Women's Health

    The Market Gen-Probe’s Meaningful —Digital —ThinPrep —Chlamydia Creates Combined & Type High Low TPPT APTIM Cervista Genotyping Imaging women’s Volume of volume Leader leading Lab Genotyping HR Mammography Cervical market Pap automation (E.g (E.g. and health incervical Test Women’s Gonorrhea Hospita

  10. Slide 10: Readily Achievable Cost Synergies

    % The Readily $75 R&D ~50% Avoid Prioritize Align Consolidate Rationalize Combined Synergies ($ inAs ofMillion women’s millions)1 millions) SSG&A assets ~40% duplicative 15.4% Achievable product $35 Spend overlapping field Run overhead and to ~10% Cost health 4.9% $30 maximize optimize service Rate

  11. Slide 11: Significant Upside from Revenue Synergies

    The women’s Significant U.S. Europe Introduce Drive Promote Highlight Capitalize Accelerate Clearly Hologic’s Utilize 11 HOLOGIC Physician compliance Hologic’s China doubles significance Gen-Probe benefits direct on market Upside Hologic’s health Force Sales market sales 500+ to of penetration Throu

  12. Slide 12: Complementary Benefit of Cross-Selling Opportunities

    The Complementary Benefit Hologic’s Combined •-Menu APTIMA Trichomonas TPPT Cervista Genotyping Molecular Cytology Physician Drive Communicate Portfolio HPV CT Women’s / NG (Human Test Compliance & from U.S. Imaging Sales Company Lab Lab Utilization significant Health physician papillomavirus) Guide

  13. Slide 13: Expected Roadmap to Closing and Integration

    Expected The Roadmap Management Integration Retention Continuity Regulatory —On Gen-Probe Women’ss June Source: 13 HOLOGIC close to ofof 18, shareholder teams authorities Completion PublicGen-Probe Team well-recognized 2012 Health August report Focused theCompany investor approvals 2012 vote waiting

  14. Slide 14: Agenda

    The Women’s Agenda Appendix 14 HOLOGICExecutive A: B: Disclaimers Non-GAAP Health Summary Company Adjustments Transaction Merits Company Overview Key Credit Strengths Historical Financial Review

  15. Slide 15: Hologic Overview

    March Overview Hologic The —Breast —Diagnostics: analysis —GYN —Skeletal women’s company Source: 15 HOLOGIC24, Surgical: is applications Health: of 2012 aHealth: Publicdeveloper, Hologic health operates Product LTM Broad Products Products company Business Revenue investor in manufacturer offerings p

  16. Slide 16: Hologic Overview: Revenue Mix

    NovaSure The Overview LTM 46% 32% Surgical Other 5% 7% Pacific Asia 58% 17% Select Selenia ThinPrep MultiCare Skeletal U.S. women’s Breast GYN Diagnostics Disposables Service Mar-2012 75% Products 13% Dimensions Pap of Stereotactic Health Health Europe Hologic health Test Revenue 25% Cervista compan

  17. Slide 17: Breast Health: Mammography Leader

    Robust The Breast Hologic’s Leader –competitive Clinical First-to-market womens Source: 17 HOLOGIC Health—Mammography in Service Breast Flagship superiority advantages health Public Offering: Cancer with and company tono investor Most of 2D Screening Recurring near-term 3DSignificant Dimensions &U.S

  18. Slide 18: 3D Dimensions Superior Tomosynthesis

    The 3D Superior Superiority Improved Lower •Tomosynthesis…Uptake U.S. On 35% Expect Dimensions womens track installed of Source: HOLOGICRecall to Next-Generation target Tissue toreach Publicover ship health Rates base achieved Tomosynthesis 2D Visualization 60% 500company Digital ofto investorof 10,

  19. Slide 19: Substantial Replacement Cycle Opportunity

    Substantial Leading -2Installed 2,000 4,000 6,000 8,000 10,000 12,000 14,000 Source: 004 2005Public Share Base—Digital 2006 3D of investor Dimensions 2007 U.S. 2008 Installed presentations Installed Opportunity 2009Base Base—Analog 2010and 2011 afilings; Growing 2012E Replacement MQSA 2013E Replacem

  20. Slide 20: Fundamental 3D Dimensions Factors

    Fundamental 3D #1: –Oslo FDA #2: Local #3: Source: Over Significant Dimensions Ongoing Competition Establish study trial Market 12,000 Public data—submitted Clinical increase Code Factors Share patients investor Among for Leadership Key Validation in3D imaged presentations cancer Regional to Dimensi

  21. Slide 21: Diagnostics: ThinPrep and Cervical Cancer Screening

    ThinPrep: Diagnostics Cervical ThinPrep Molecular Cervista •HPV Source: U.S.Screening Significant Growth Utilizes Serves Recent market Public mid HPV approvals Cancer opportunity powerful Pap Steady Diagnostics: EBITDA and share Test HR investor &Screening low US & Diagnosis & in ThinPrep ~16/18 Rel

  22. Slide 22: GYN Surgical: Addressing Abnormal Uterine Bleeding

    GYN Addressing Abnormal NovaSure Uterine •MyoSure Source: ClearSurgical Standard Double-digit Minimally-invasive Maintains leader Fibroids Public Uterine ofSubstantial uterine care with annual investor and Bleeding ~form Polyps 60-65% technology growth Unmet presentations and function current expect

  23. Slide 23: R&D Investment Drives Innovation

    R&D Steady U.S. •International Source: Trident 3D FDA Sentinelle Serenity C-View Cervista Dimensions Investment Pace Public Specimen (CE digital HPV MTA approvals Prostate 16-channel of approvals Marking) investor Recent High-Throughput HR Medium-Throughput mammography Tomosynthesis Drives Radiograp

  24. Slide 24: Gen-Probe Overview

    Overview Gen-Probe The —Clinical —Blood Fully Best-in-class March Source: company automated 31, Public Screening: of 2012 Diagnostics: isGen-Probe assays aoperates investor global LTM TIGRIS with Develops Revenue leader inpresentations Market Business and leading twoinPANTHER main reagents and blood

  25. Slide 25: Gen-Probe Overview: Revenue Mix

    Overview LTM 4% 61% Other 28% North 35% Blood Select Screening APTIMA PANTHER Assay Source: Clinical America Rest Mar-2012 Diagnostics Assay Products the Public HPV of World TIGRIS Gen-Probe investor Trichomonas Revenue 72% PROCLEIX presentations Business by Business Mixand Segment andfilings Produc

  26. Slide 26: TIGRIS High-Volume Automation

    TIGRIS High-Volume Launched —APTIMA 700 —PROCLEIX 500 Integrated, 300 0sthat Clinical —Actively Among —Demonstrates —More labs —Average 1Source: teps Allautomates placement 2007 most Public Diagnostics than System in2008 high-throughput diagnostics defending STD 2004 640 successful Labs all investor

  27. Slide 27: PANTHER System Offers Flexibility

    PANTHER Offers —Drives —Increases —Provides Builds —Flexibility, Capabilities Commercial –—Launched —Approved Source: Achieved automation onPublic growth success opportunity full System 2011 access of in Status functionality chemistry, investor Europe U.S. automation placement from of to to Offers f

  28. Slide 28: Gen-Probe Chlamydia/Gonorrhea Franchise

    Gen-Probe Chlamydia —CDC —HEDIS $492 —$344 —$148 APTIMA —Sustainable —Gen-Probe Source: 28 million million and reported COMBO data STD and Public market estimates competitive indicates gonorrhea inFranchise ex-U.S., 1.3 U.S., investor 2million inassay, 2011 they +3% that +10% are advantage Remains G

  29. Slide 29: New Assays: Trichomonas and HPV

    New —~$275 —Runs —HPV APTIMA –—Trichomonas —Assay Source: If untreated Studies APTIMA causes testing Public on targets FDA million indicate Trichomonas HPV TIGRIS can cleared Assays cervical investor is Assay vaginalis disease U.S. highly cause it system potentially market inAssay cancer presentatio

  30. Slide 30: Blood Screening Franchise

    Blood Portfolio Franchise —Approximately —Leading —Underlying Key —More Partnership Over Source: PROCLEIX time, Screening Public than of enhancing global growth with Best-in-Class 370 donation investor Novartis products TIGRIS market 35% opportunities segment of volumes presentations share product p

  31. Slide 31: Novartis Exclusive Collaboration

    Novartis Exclusive —Gen-Probe —Assays Collaboration —Enables —Collaboration Attractive —50/50 —Revenue 2011 Gen-Probe Source: 2012Public responsibility Collaboration run collaboration economics both 2013 Share share responsible exclusively extended investor companies 2014 survives for 46%HCV-contain

  32. Slide 32: Agenda

    Executive A: Agenda Appendix B: Summary Disclaimers Non-GAAP Transaction Adjustments 32 Merits Company Overview Key Credit Strengths Historical Financial Review

  33. Slide 33: Key Credit Strengths

    Key Credit Market Significant Attractive 33 Leader Credit Free Strengths inCash Profile Key Flow Products with Generation Meaningful Diversified Drives Equity andExpected Balanced Value Deleveraging Revenue Mix Best-in-Class Technologies Broad International Presence Experienced and Proven Management

  34. Slide 34: Market Leader in Key Products

    Breastcampaign Uterine Menorrhagia Imaging Combined Densitometer QDR Polyps ThinPrep Offering C-Arm Sonometer ~53% Position ~65% market (U.S.) Market Further DTC Additional International Opportunities awareness technology Source: 34 of ~70% (U.S.) Cervical share Imaging Leader #1 Share Size Growth a

  35. Slide 35: Diversified Combined Revenue Mix

    Diversified As Combined 5% Health ($95mm) 17% Surgical ($309mm) 4% Other ($22mm) Source: ($205mm) Screening Blood 35% (50% 38% ($0.3bn) 86% ($0.9bn) 35$1.2bn) of Skeletal 61% Women’ Women’s 32% Diagnostics March Diagnostics Breast Public Diagnostics 12% ($858mm) ($360mm) Company ($600mm) and 46% 201

  36. Slide 36: Best-in-Class Technologies

    Best-in-Class Combination Recent Leading growth Mammography bleeding Combined technologies Breast …with Source: 36 Health product aPublic U.S. (NovaSure) focus company &of market Technolo Surgical investor onintroductions (Selenia leading R&D has share Diagnostics iesg presentations diagnostics to ~

  37. Slide 37: Broad International Presence

    Broad International Combining presence Direct Distribution Source: 37 Sales Public with Hologic’s Partner ~550 investor Presence international worldwide presentations representatives direct andsales filings force doing and distribution business in over partners 150 with countries Gen-Probe’s Intent

  38. Slide 38: China and Emerging Markets Opportunity

    With 2011 Two TCT Healthcome –China Enhancing ThinPrep Cervista Utilizing Source: 38Improving Hospital recent Medical Significant Investments expected Public HPV the (existing) construction the acquisitions –healthcare model –HR Manufacturer infrastructure investor Market toEmerging and test, betoma

  39. Slide 39: Experienced and Proven Management Team

    Experienced Hologic’s Name Title CEO, Glenn CFO, Mark Tom Secretary David Peter Steve Robert Jay Steven CEO History Over ranging Executive CFO Previously Prior, Managed SVP, 25 SVP VP, Co-founder Joined Has 1Source: 39 years A. Corporate served and Umbel Company1 of Chief Human Business Finance 20 K

  40. Slide 40: Significant Cash Flow Drives Deleveraging

    Significant Pro Cash management Hologic 4.2x 6/30/2007 1.7x 2.0x 2.7x 3.6x Total Mar. Source: Combined $516 $126 $390 Note: 1(took 40 Forma 4.1x 2012 flow Net leverage September Public Historical Calculated Debt 6/30/2008 should LTM LTM Free asfrom filings, $2,220 demonstrated Operating Cash net Hol

  41. Slide 41: Attractive Credit Profile with Meaningful Equity Value

    Attractive ($ Conservatively ~$4.8 guaranteed Significant Coverage $9,405 Enterprise $3,500 Secured Total Guaranteed ²¹Source: 41 As Debt inof millions) Leverage billion¹ balances May Bloomberg, Leverage of: Credit Value by pro Enterprise Debt 2,Secured Hologic’s Value 2012. forma capitalized pro Pr

  42. Slide 42: Agenda

    Executive A: Agenda Historical Appendix 42 Financial B: Summary Disclaimers Non-GAAP Review Transaction Adjustments Merits Company Overview Key Credit Strengths

  43. Slide 43: Hologic Historical Financials

    Hologic ‘09 $1,637 FY $634 $611 $605 $603 $1,862 $1,789 Adj. % SG&A, 37% 36% 34% Adjusted Source: 1Reconciliation 43 Rev 2009A –Gross EBITDA 62% ‘11 R&D, $1,680 % Public Historical EBITDA Revenue 7% 6% Rev FY Margin, %23% 24% 25% Margin 2010A investor to Rev non-GAAP CAGR Revenue FYpresentations 201

  44. Slide 44: Gen-Probe Historical Financials

    Gen-Probe ‘09 FY $188 $587 $191 $576 $185 $543 $167 $498 Adj. % SG&A, 34% 33% 32% Adjusted Revenue Source: 1Reconciliation 44 Rev 2009A –Gross EBITDA 70% 69% ‘11 R&D, % Public EBITDA Revenue 21% 20% 19% Rev FY Historical Margin, % Margin 2010A investor 23% 21% 24% to Revnon-GAAP CAGR Revenue FYprese

  45. Slide 45: Selected Combined Historical Financials

    Selected ($ Revenue $2,135 $2,223 $2,366 $2,449 $1,366 $1,406 $1,507 $1,556 Adjusted ‘09-’11 $770 $790 $802 $897 Capital $90 $78 $98 $$102 FY $75.0mm Source: Hologic Gen-Probe 451,637 543 1,680 576 1,789 587 1,862 346 1,020 374 1,032 1,104 403 1,153 603 605 611 188 634 42 56 40 62 in2009A $millions)

  46. Slide 46: Agenda

    Executive A: Agenda Appendix 46 B: Summary Disclaimers Non-GAAP Transaction Adjustments Merits Company Overview Key Credit Strengths Historical Financial Review Financing Overview Questions & Answers

  47. Slide 47: Hologic Adjusted EBITDA Reconciliation

    Hologic ($ September 26, NET GAAP Amortization Adjustments Non-cash Contingent Adiana Gain Acquisition-related Restructuring Litigation Fair Goodwill Other-than-temporary Acquired Income Non-GAAP EBITDA Interest Provision Depreciation Cost Adjusted Source: 321Note: 47 2015. For Represents in2009 val

  48. Slide 48: Gen-Probe Adjusted EBITDA Reconciliation

    Gen-Probe ($ Year 2009 Ended NET GAAP Amortization Adjustments Restructuring, Goodwill Gain Other-than-temporary Non-GAAP EBITDA Interest Income Depreciation Adjusted Source: 48 in Ended millions) INCOME on 2010 net income, tax Public contingent EBITDA and income 2011 Reconciliation effect expense D

  49. Slide 49: Adjusted Gross Profit Reconciliation

    Reconciliation ($ Hologic Twelve Year September 26, GAAP Adjustments Fair Cost intangible Product Non-GAAP Adjusted Source: 49 in2009 value of Ended millions) Gross product Months Public line Actual 25, Gross assets write-up September Ended adjustments closure 2010 Profit of filings Consolidated Pro

  50. Slide 50: Agenda

    Executive A: Agendag Appendix 50 Summary Non-GAAP Transaction Adjustments Overview Company Overview Key Credit Strengths Historical Financial Review

  51. Slide 51: Forward-Looking Statements

    Forward-Looking This limitation, permanent “expect,” statements parties manner anticipated unknown, combined retain above Hologic or 51 circumstances presentation key are toor expressly consummate “believe,” not company employees. underestimated at statements financing are financing all, exhaustive.

  52. Slide 52: Trademark Notice

    Trademark Hologic following: MammoSite, TCT, ACCUPROBE, PRODESSE, and All does 52 other ULTRIO not TLIis imply brand IQ, Adiana, aNotice trademark MultiCare, PROFAST, are Trident, that names AMPLIFIED trademarks Aegis, Hologic Trimark, or ofMyoSure, PROFLU, trademarks Hologic, Affirm, or ofMTD, Gen-

  53. Slide 53: Use of Non-GAAP Financial Measures

    Useconvertible Hologic income contingent shareholders of that product acquisition The activities, settlements, non-GAAP spending. business. and 53 accounts gross may reconciliations Company of Non-GAAP and sales-impairment has not When profit As noncash consideration related adjusted receivable adju

Hologic — Debt Investor Presentation (June 2012) on 6ix